Lovastatin (Synonyms: 洛伐他汀; Mevinolin)

目录号: HY-N0504 纯度: 99.64%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Lovastatin是一种用于降低胆固醇的细胞渗透性的 HMG-CoA还原酶抑制剂。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Lovastatin Chemical Structure

CAS No. : 75330-75-5

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥500	In-stock
50 mg	￥599	In-stock
100 mg	￥871	In-stock
200 mg	￥1200	In-stock
500 mg		询价
1 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Lovastatin:

MCE 顾客使用本产品发表的 22 篇科研文献

: Lovastatin purchased from MCE. Usage Cited in: Antiviral Res. 2022 Dec 15;209:105497. [Abstract]; Pretreatment with AY9944 (15, 30 µM), U18666A (5, 10 µM), lovastatin (5, 10 µM) and MβCD for 2 h can all significantly reduce the level of EV-A71 VP1 protein in HCT-8 cell.

Lovastatin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.

IC₅₀ & Target

HMG-CoA reductase^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	11.4 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 23570542]
A549	IC₅₀	19.8 μM Compound: 1	Inhibition of HMG-CoA reductase in human A549 cells after 5 mins by spectrophotometric analysis Inhibition of HMG-CoA reductase in human A549 cells after 5 mins by spectrophotometric analysis	[PMID: 23570542]
HepG2	IC₅₀	37 nM Compound: mevinolin (lactone) 2	Concentration required to inhibit HMG-CoA reductase by 50% was determined in Hep G2 cell line Concentration required to inhibit HMG-CoA reductase by 50% was determined in Hep G2 cell line	[PMID: 1527791]
HepG2	IC₅₀	50 nM Compound: 1b (Mevinolin)	Inhibition of cellular HMG-CoA reductase in cultures of human HEP G2 cells, determined by decreased incorporation of sodium [14C]acetate into cholesterol. Inhibition of cellular HMG-CoA reductase in cultures of human HEP G2 cells, determined by decreased incorporation of sodium [14C]acetate into cholesterol.	[PMID: 2296036]
HepG2	IC₅₀	8.3 μM Compound: Lovastatin	Lipid lowering activity in human HepG2 cells assessed as decrease in oleic acid elicited lipid accumulation after 6 hrs by oil-red O staining method Lipid lowering activity in human HepG2 cells assessed as decrease in oleic acid elicited lipid accumulation after 6 hrs by oil-red O staining method	[PMID: 26169125]
HES	IC₅₀	13 nM Compound: mevinolin (lactone) 2	Concentration required to inhibit HMG-CoA reductase by 50% was determined in HES 9 cell line Concentration required to inhibit HMG-CoA reductase by 50% was determined in HES 9 cell line	[PMID: 1527791]
Hs68	IC₅₀	23.2 μM Compound: 1	Cytotoxicity against human HS68 cells after 72 hrs by MTT assay Cytotoxicity against human HS68 cells after 72 hrs by MTT assay	[PMID: 23570542]
HT-29	IC₅₀	46.8 μM Compound: Lovastatin	Growth inhibition of human HT29 cells after 96 hrs by MTS assay Growth inhibition of human HT29 cells after 96 hrs by MTS assay	[PMID: 17472962]
KB	IC₅₀	15.6 μM Compound: 2	Cytotoxicity against human KB cells by resazurin microplate assay Cytotoxicity against human KB cells by resazurin microplate assay	[PMID: 27228159]
LS180	IC₅₀	25.3 μM Compound: Lovastatin	Growth inhibition of human LS180 cells after 96 hrs by MTS assay Growth inhibition of human LS180 cells after 96 hrs by MTS assay	[PMID: 17472962]
MCF7	IC₅₀	> 40 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 to 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 to 48 hrs by MTT assay	[PMID: 27756564]
MDA-MB-231	IC₅₀	> 40 μM Compound: 1	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 to 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 to 48 hrs by MTT assay	[PMID: 27756564]
MEF	IC₅₀	35 μM Compound: 1	Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay	[PMID: 23570542]
PC-3	IC₅₀	5.4 μM Compound: 1	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27756564]
SW480	IC₅₀	7.1 μM Compound: Lovastatin	Growth inhibition of human SW480 cells after 96 hrs by MTS assay Growth inhibition of human SW480 cells after 96 hrs by MTS assay	[PMID: 17472962]
T47D	IC₅₀	> 40 μM Compound: 1	Cytotoxicity against human T47D cells assessed as growth inhibition after 24 to 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as growth inhibition after 24 to 48 hrs by MTT assay	[PMID: 27756564]
THP-1	IC₅₀	8 μg/mL Compound: Lovastatin	Inhibition of sICAM1/LFA1 interaction-mediated human THP1 cell adhesion after 1 hr by ELISA Inhibition of sICAM1/LFA1 interaction-mediated human THP1 cell adhesion after 1 hr by ELISA	[PMID: 18672369]

体外研究
(In Vitro)

Lovastatin (10 μM；72 hours) 有效降低 HepG2 细胞活力^[2]。
Lovastatin (10 μM；48 hours) 诱导 HepG2 细胞凋亡^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	HepG2 cells
Concentration:	10 μM
Incubation Time:	72 hours
Result:	Efficiently reduced viability of HepG2 cells.

体内研究
(In Vivo)

Lovastatin 是一种无活性内酯，在肝脏中水解为活性 f3-羟基酸形式。这种主要代谢物是 HMG-CoA 还原酶的抑制剂。K_i 为 1 nM。Lovastatin 及其 β-羟基酸代谢物与人血浆蛋白高度结合。Lovastatin 可穿过血脑屏障和胎盘屏障^[3]。Lovastatin 可显著降低含载脂蛋白 B 的脂蛋白，尤其是 LDL 胆固醇，并在较小程度上降低血浆甘油三酯，并略微增加 HDL 胆固醇^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

404.54

Formula

C₂₄H₃₆O₅

CAS 号

75330-75-5

性状

固体

颜色

Off-white to light yellow

中文名称

洛伐他汀；辛伐他汀EP杂质E

结构分类

Ketones, Aldehydes, Acids

初始来源

微生物

aspergillus terreus

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 100 mg/mL (247.19 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4719 mL	12.3597 mL	24.7194 mL
5 mM	0.4944 mL	2.4719 mL	4.9439 mL
10 mM	0.2472 mL	1.2360 mL	2.4719 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.18 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.18 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.18 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.89%

选择批次：

Data Sheet (642 KB) SDS (418 KB)

COA (293 KB) LCMS (154 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Alberts AW, et al. Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 1988 Nov 11;62(15):10J-15J. [Content Brief]

[2]. Kah J, et al. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep. 2012 Sep;28(3):1077-83. [Content Brief]

[3]. Frishman WH, et al. Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol. Med Clin North Am. 1989 Mar;73(2):437-48. [Content Brief]

[4]. Tobert JA, et al. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. [Content Brief]

[5]. Ifergan I, et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol. 2006 Jul;60(1):45-55. [Content Brief]

Lovastatin 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.4719 mL	12.3597 mL	24.7194 mL	61.7986 mL
	5 mM	0.4944 mL	2.4719 mL	4.9439 mL	12.3597 mL
	10 mM	0.2472 mL	1.2360 mL	2.4719 mL	6.1799 mL
	15 mM	0.1648 mL	0.8240 mL	1.6480 mL	4.1199 mL
	20 mM	0.1236 mL	0.6180 mL	1.2360 mL	3.0899 mL
	25 mM	0.0989 mL	0.4944 mL	0.9888 mL	2.4719 mL
	30 mM	0.0824 mL	0.4120 mL	0.8240 mL	2.0600 mL
	40 mM	0.0618 mL	0.3090 mL	0.6180 mL	1.5450 mL
	50 mM	0.0494 mL	0.2472 mL	0.4944 mL	1.2360 mL
	60 mM	0.0412 mL	0.2060 mL	0.4120 mL	1.0300 mL
	80 mM	0.0309 mL	0.1545 mL	0.3090 mL	0.7725 mL
	100 mM	0.0247 mL	0.1236 mL	0.2472 mL	0.6180 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Lovastatin75330-75-5Mevinolin洛伐他汀辛伐他汀EP杂质EHMG-CoA Reductase (HMGCR)AutophagyFerroptosisInhibitorinhibitorinhibit

您最近查看的产品:

产品名称：

* 需求量：

* 客户姓名：

* Email：

* 电话：

* 公司或机构名称：

留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4

上海工商

沪公网安备31011502019417

沪(浦)应急管危经许[2021]201709(QFYS)

营业执照（三证合一）

Lovastatin (Synonyms: 洛伐他汀; Mevinolin)

Customer Review

Other Forms of Lovastatin:

MCE 顾客使用本产品发表的 22 篇科研文献